SCHEMBL30732268

SCHEMBL30732268

CC(C)(C)OC(=O)N1C[C@@H]2C(CN3CCN(C(=O)OCc4ccccc4)CC3)[C@@H]2C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ PARP1 P09874 1/20 0.48
▸ HTT P42858 1/20 0.47
▸ CYP2C19 P33261 1/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ CHRM2 P08172 1/20 0.45
▸ CHRM4 P08173 1/20 0.45
▸ CHRM1 P11229 1/20 0.45
▸ CHRM3 P20309 1/20 0.45
▸ PDK1 Q15118 1/20 0.45
▸ PDK2 Q15119 1/20 0.45
▸ PDK3 Q15120 1/20 0.45
▸ PDK4 Q16654 1/20 0.45
▸ JAK2 O60674 1/20 0.45
▸ JAK1 P23458 1/20 0.45
▸ STS P08842 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25338897 0.89 SMN1; SMN2 (0.50) SMN1; SMN2NPC1RAB9APARP1HTT
SCHEMBL20046470 0.89 SMN1; SMN2 (0.50) SMN1; SMN2NPC1RAB9APARP1HTT
SCHEMBL26925309 0.87 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9APARP1HTT
SCHEMBL26925305 0.87 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9APARP1HTT
SCHEMBL29132380 0.86 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9APARP1HTT
SCHEMBL29579133 0.85 SMN1; SMN2 (0.49) SMN1; SMN2NPC1RAB9APARP1HTT
SCHEMBL1842426 0.85 MEN1 (0.61) SMN1; SMN2NPC1RAB9APARP1HTT
SCHEMBL2386800 0.85 SMN1; SMN2 (0.56) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL34473618 0.85 SMN1; SMN2 (0.50) SMN1; SMN2NPC1RAB9APARP1HTT
SCHEMBL18921646 0.85 SMN1; SMN2 (0.56) SMN1; SMN2NPC1RAB9AHTTCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2025-09-04 — — US disclosed
EP-4536650-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2025-04-16 — — EP disclosed
EP-4536658-A1 1,8-NAPHTHYRIDIN-2-ONE HETEROBIFUNCTIONAL BCL6 DEGRADERS Treeline Biosciences, Inc. (US) 2025-04-16 — — EP disclosed
CN-119317623-A Tricyclic quinolone BCL6 bifunctional degradation agents 树线生物科学公司 2025-01-14 — — CN disclosed
US-20240287091-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2024-08-29 — — US disclosed
WO-2023240038-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2023-12-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287091-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR SMN1; SMN2 4565/4885NPC1 1801/4885RAB9A 3447/4885
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR SMN1; SMN2 4565/4885NPC1 1801/4885RAB9A 3447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback